Last reviewed · How we verify
NCT02608411: TIMES
TIvantinib as Maintenance Treatment in Extended Small-cell Lung Cancer (TIMES)
Phase 2 trial testing ARQ197 in Carcinoma, Small Cell in 5 participants. Terminated before completion.
21 February 2017
Quick facts
| Lead sponsor | Istituto Oncologico Veneto IRCCS |
|---|---|
| Phase | Phase 2 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 5 |
| Start date | 19 February 2016 |
| Primary completion | 21 February 2017 |
| Estimated completion | 21 February 2017 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- ARQ197 — full drug profile →
Conditions studied
- Carcinoma, Small Cell — all drugs for Carcinoma, Small Cell →
Sponsor
Istituto Oncologico Veneto IRCCS — full company profile →
Who can join
18 and older, any sex, with Carcinoma, Small Cell. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to assess the role of MET inhibitors as maintenance treatment in adult patients with extensive stage small cell lung cancer.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Advancements in the Understanding of Small-Cell Neuroendocrine Cervical Cancer: Where We Stand and What Lies Ahead.
Wang Y, Qiu H, Lin R, Hong W, et al · · 2024 · cited 5× · PMID 38793044 · DOI 10.3390/jpm14050462
Verify or expand the search:
- PubMed search for NCT02608411
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Carcinoma, Small Cell
Currently open trials in the same condition.
- NCT04660929 — CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors · Phase 1 · active not recruiting
Other Istituto Oncologico Veneto IRCCS trials
Trials by the same sponsor.
- NCT07185568 — IntraOperative UltraSound Guided vs Wire Guided vs Magnetic Seed Guided Breast-Conserving Surgery for Non-palpable Tumor · NA · not yet recruiting
- NCT07338292 — VIrtual Reality Induced Pain and anxiEty Relief in Outpatient UROlogical Procedures · NA · recruiting
- NCT06753136 — Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histo · NA · recruiting
- NCT06595498 — Next Generation Sequencing Method for the Detection of EGFR Gene Mutations in the Plasma of Patients With Lung Cancer · NA · active not recruiting
- NCT06600568 — Novel Therapeutic Approach for Human T-cell Malignancies · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02608411 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Istituto Oncologico Veneto IRCCS
- Last refreshed: 13 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02608411.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing